Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 |Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, and others.
DelveInsight’s, “Diabetes Pipeline Insights 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Diabetes Pipeline Report
- DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
- The leading companies working in the Diabetes Market include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Promising Diabetes Pipeline Therapies in the various stages of development include LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.
- November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
- September 2023: Adocia announced a study of Phase 1 clinical trials for Euglycemic clamp with BC Combo THDB0207. This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects with type 2 diabetes. Each subject will be randomly allocated to one of four treatment sequences. Each sequence will comprise 3 different single doses of BC Combo THDB0207 (Low dose, Medium dose, and High dose) and one single dose of Humalog® Mix25.
Request a sample and discover the recent advances in Diabetes Treatment Drugs @ Diabetes Pipeline Outlook Report
The Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diabetes clinical trial landscape.
Diabetes Overview
Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.
Find out more about Diabetes Treatment Landscape @ Drugs for Diabetes Treatment
Diabetes Emerging Drugs Profile
- Enavogliflozin – Daewoong
- Golimumab – Janssen Biotech
Diabetes Pipeline Therapeutics Assessment
There are approx. 200+ key companies which are developing the therapies for Diabetes. The Diabetes companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.
DelveInsight’s Diabetes Pipeline Report covers around 200+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Diabetes Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Diabetes Pipeline Therapies @ Diabetes Clinical Trials Assessment
Scope of the Diabetes Pipeline Report
- Coverage- Global
- Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
- Diabetes Pipeline Therapies- LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.
Dive deep into rich insights for new drugs for Diabetes treatment, Visit @ Diabetes Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Diabetes: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diabetes – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Diabetes Collaboration Deals
- Late Stage Products (Phase III)
- Enavogliflozin: Daewoong
- Mid Stage Products (Phase II)
- Golimumab: Janssen Biotech
- Early Stage Products (Phase II/I)
- IMCY-0098: ImCyse
- Pre-clinical and Discovery Stage Products
- ENT-001: Enthera
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetes Key Companies
- Diabetes Key Products
- Diabetes- Unmet Needs
- Diabetes- Market Drivers and Barriers
- Diabetes- Future Perspectives and Conclusion
- Diabetes Analyst Views
- Diabetes Key Companies
- Appendix
For further information on the Diabetes pipeline therapeutics, reach out @ Diabetes Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market
